Lower extremity artery disease Lower extremity artery disease
Conditions
Interventions
Sponsors
Otake Hiromasa
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) LEAD patients scheduled to undergo elective EVT for femoropopliteal or below-knee ar tery lesions (2) Patients whose lesions to be treated were determined to be non-calcified lesions (3) Patients with lesions >4 mm in reference vessel diameter on preoperative angiography or CT examination (4) Patients who are 18 years of age or older at the time of informed consent (5) Patients who can understand the content of the treatment and the purpose of the research, and who are able to obtain written informed consent of their own free will.
Exclusion criteria
Exclusion criteria: (1) Patients with acute limb ischemia or acutethrombosis (2) In-stent stenosis or occlusive lesion (3) Rutherford Category 6, or Critical limb ischemia suspected of widespread infection (4) Patients who find it difficult to continue antiplatelet therapy (such as patients planning surgery that requires withdrawal of antiplatelet agents within one month) (5) Patients who are pregnant/lactating or may be pregnant (6) Other patients who are judged inappropriate by the principle investigator or subinvestigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Molecular biological characteristics in single-cell RNA sequence analysis of lower extremity atheroscrelotic plaque obtained by DCA (Comprehensive analysis of disease-related genes or mRNA) | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety endpoint: Presence or absence of complications during the procedure or perioperative period | — |
Contacts
Public ContactTakayoshi Toba
Kobe University hospital
Outcome results
None listed